Humana Inc. (HUM) fair value analysis
S&P 500 · Updated 2026-09-07
Humana Inc. is a healthcare company that provides health insurance coverage and related healthcare services to millions of individuals. The company operates throughout the United States, serving customers through various insurance products including Medicare, Medicaid, and commercial health plans.
Forward Fair Value verdict
OvervaluedBased on TickrTrends' weekly Forward Fair Value model, HUM is trading at more than a 25% premium to estimated fair value.
HUM currently ranks #109 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Overvalued for 3 consecutive weekly runs.
- Last price
- $401.54
- Sector
- Healthcare
- 12-month range
- $176.95–$394.88
Derived indicators
Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.
- Quality grade
- C
- Leverage
- Moderate
- Margin trend
- Stable
- Revenue growth
- Strong
- RSI zone
- Neutral
- 52-week position
- The top quarter of its range
- DCF cross-check
- Fairly Valued
What our data shows for HUM
- Our model validated 17 trailing price-to-earnings windows for HUM, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $176.95–$394.88.
- The 14-day relative strength index sits at a neutral 65.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for HUM
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
How Forward Fair Value works
TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.
Recent HUM news
TickrTrends' derived news-sentiment signal for HUM is currently leaning positive, computed from recent coverage.
- Insurers Have Already Told Wall Street Which Advantage Plans Die on December 31. Members Are the Last to Know, and the Letter Isn’t Due Until October 2. (finance.yahoo.com, 2026-09-05)
TickrTrends take: Humana's pending disclosure of Medicare Advantage plan discontinuations represents a material information event that could affect member retention and revenue predictability heading into the new year. Given TickrTrends' overvalued assessment, investors should monitor whether the scope of plan exits and associated member migration patterns support the current valuation or suggest further downside risk. The October 2 deadline for member notification creates a defined catalyst for market reassessment of Humana's growth trajectory and competitive positioning in the Medicare Advantage segment. - Can Better Star Ratings and Margin Expansion Drive Humana (HUM) Higher? (finance.yahoo.com, 2026-09-03)
TickrTrends take: Humana operates in the Healthcare sector where TickrTrends currently derives an Overvalued verdict for HUM. While improvements to Star Ratings and margin expansion represent potential operational strengths, valuation-focused readers should monitor whether such operational gains can justify the current price relative to fundamental metrics. The execution risk on margin expansion in a competitive healthcare environment will be a key factor in assessing whether the stock's current valuation can be supported by actual financial results. - HUM Looks 5.8% Overvalued on GF Value™ as Dividend Holds Steady (gurufocus.com, 2026-09-02)
TickrTrends take: Humana Inc. currently trades at a premium to its intrinsic value estimate according to GF Value metrics, which aligns with TickrTrends' assessment that the stock appears overvalued. For investors focused on valuation discipline in the Healthcare sector, the maintenance of the dividend despite the stock's valuation premium suggests management confidence, though it also means current buyers are paying above calculated fair value for their income stream. Valuation-conscious investors typically monitor whether such premiums compress through price decline or earnings growth that eventually justifies the current level.
What people are saying
Follow the HUM conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-09-07 — TickrTrends' derived indicators for HUM showed a shift this week in the DCF cross-check band, moving from an overvalued assessment to a fairly valued assessment. Despite this improvement in the DCF analysis, the current overall valuation verdict for HUM remains overvalued as of this week.
- 2026-09-06 — HUM's valuation status shifted this week as TickrTrends' DCF cross-check band moved from fairly valued to overvalued. The current valuation verdict categorizes the stock as overvalued within the Healthcare sector.
- 2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is HUM stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), HUM is trading at more than a 25% premium to estimated fair value and screens as overvalued. The exact fair value and discount are available to subscribers.
What is HUM's TickrTrends verdict?
HUM's current verdict is Overvalued, refreshed with every weekly Forward Fair Value run.
How does HUM compare to other Healthcare stocks?
HUM ranks #109 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.
Is HUM overbought or oversold?
HUM's 14-day RSI is in neutral territory - neither overbought nor oversold.
More in Healthcare
Head-to-head comparisons
HUM vs ACAD · HUM vs ALKS · HUM vs AMGN · HUM vs CDNA · HUM vs DGX